LONDON, March 19, 2014 /PRNewswire/ --
The US markets saw a positive sentiment on Tuesday, March 18, 2014, as the NASDAQ Composite
closed at 4,333.31, up 1.25%, the Dow Jones Industrial Average
ended the session at 16,336.19, up 0.55% and the S&P 500 edged
0.72% higher to finish the trading session at 1,872.25. During the
session, gains in the Information Technology, Health Care, and
Energy sectors positively impacted the broader market. A number of
stocks saw large movements, including Genco Shipping & Trading
Ltd (NYSE: GNK), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX),
Rambus Inc. (NASDAQ: RMBS), and Exact Sciences Corp. (NASDAQ:
EXAS). Free technical research on GNK, PGNX, RMBS, and EXAS can be
downloaded upon signing up at:
http://www.investor-edge.com/325-register
Shares in Genco Shipping & Trading Ltd closed Tuesday's session
at $1.58, up 8.22%, with a trading
volume of 1.90 million shares as compared to a three months average
volume of 1.69 million shares. The stock oscillated between
$1.43 and $1.59 during the trading
session. Shares of Genco Shipping & Trading Ltd have advanced
7.48% in the previous three trading sessions, while the same has
fallen by 12.22% in the last one month and 36.80% on YTD basis. The
S&P 500 Industrials Sector Index mapped a gain of 0.50% during
the trading session and charted up 1.45% in the last one month.
Moreover, the stock is trading at the RSI of 34.90 and below its
50-day and 200-day moving averages of $1.98 and $2.38,
respectively. Sign up today to read free research on GNK at:
http://www.investor-edge.com/325-GNK-19Mar2014.pdf
On Tuesday, shares in Progenics Pharmaceuticals Inc. ended the
session at $4.74, up 9.42% from the
previous day's closing price of $4.33. A total of 2.23 million shares were traded
as compared to a three months average volume of 1.46 million
shares. The stock traded between $4.29 and
$4.88 during the trading session. Shares in Progenics
Pharmaceuticals Inc. have gained 8.67% in the previous three
trading sessions and 0.59% in the last three months, while the same
has lost 11.11% on YTD basis. The S&P 500 Health Care Sector
Index mapped a gain of 1.17% during the trading session and charted
up 1.47% in the last one month. Furthermore, the stock is trading
at the RSI of 39.01 and below its 50-day and 200-day moving
averages of $5.28 and $4.95, respectively. Sign up today to read free
research on PGNX at:
http://www.investor-edge.com/325-PGNX-19Mar2014.pdf
Rambus Inc.'s stock finished Tuesday's session at $10.56, recording a gain of 6.56%. A total of
2.26 million shares were traded which is above the three months
average volume of 0.98 million shares. The stock fluctuated between
$9.85 and $10.80 during the session.
Rambus Inc.'s shares have surged 7.87% in the previous three
trading sessions, 13.30% in the last one month and 11.51% on YTD
basis. The S&P 500 Information Technology Sector Index mapped a
gain of 1.35% during the trading session and charted up 1.13% in
the last one month. Additionally, the stock is trading at the RSI
of 64.16 and above its 50-day and 200-day moving averages of
$9.14 and $9.03, respectively. Sign up today to read free
research on RMBS at:
http://www.investor-edge.com/325-RMBS-19Mar2014.pdf
Exact Sciences Corp.'s stock gained 9.82% on Tuesday, closing the
session at $14.42. A total of 1.79
million shares were traded as compared to a three months average
volume of 0.96 million shares. The stock vacillated between
$13.17 and $14.45 during the session.
Exact Sciences Corp.'s shares have rallied 13.72% in the last one
month, 20.07% in the previous three months and 22.72% on YTD basis.
The S&P 500 Health Care Sector Index advanced 1.17% during the
trading session and charted up 8.57% in the previous three months.
Furthermore, the stock is trading at the RSI of 45.49 and above its
50-day and 200-day moving averages of $13.45 and $12.54,
respectively. Sign up today to read free research on EXAS at:
http://www.investor-edge.com/325-EXAS-19Mar2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge